Treatment pattern of Alzheimer's disease with cholinesterase inhibitors (TRAIN study);Patrón de tratamiento de la enfermedad de Alzheimer con inhibidores colinesterásicos (estudio TRAIN)

Revista de Neurologia

Volumn 46, Issue 8, 2008, Pages 461-464

  Gil Néciga, Eulogio ^a   Gobartt, A L ^b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b Unidad de Health Outcomes Research   (Spain)

Author keywords

Alzheimer's disease; Anticholinesterases; Donepezil; Galantamine; Memantine; Rivastigmine

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE;

AGED; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; EPIDEMIOLOGICAL DATA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MINI MENTAL STATE EXAMINATION; MONOTHERAPY; OUTPATIENT; PSYCHIATRIST; TREATMENT OUTCOME;

EID: 44449169055     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4608.2008131     Document Type: Article

References (10)

1. Kaduszkiewicz H, Zimmerman T, Beck-Bernholdt H, Van den Busche H. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ 2006; 331: 321-7.
2. Birks J. Cholinesterase inhibitors for Alzheimer's disease (review). The Cochrane Library 2006, Issue 2. Cochrane Database Syst Rev 2006; 1: CD005593.
3. American Medical Association. Practical guide for the primary care physician on the diagnosis, management, and treatment of dementia. Chicago, IL: AMA; 1999.
4. Boustani M, Peterson B, Hanson L, Harris R, Lohr KN. Screening for dementia in primary care: a summary of the evidence for the US Preventive Task Force. Ann Intern Med 2003; 138: 927-37.
5. Fillit H, Smith-Doody R, Binaso K, Crook GM, Ferris SH, Farlow MR, et al. Recommendations for best practices in the treatment of Alzheimer's disease in managed care. Am J Geriatr Pharmacother 2006; 4 (Suppl): S9-24.
6. National Institute for Health and Clinical Excellence. Alzheimer's disease -donepezil, rivastigmine, and memantine: appraisal consultation document. URL: http://www.nice.org.uk [30.06.2005].
7. National Institute for Health and Clinical Excellence. Donepezil, galantamine, rivastigmine (review), and memantine for the treatment of Alzheimer's disease: NICE Technology Appraisal Guidance TA111. URL: http://www.nice.org.uk [17.11.2006].
8. Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 2005; 21: 1317-27.
9. González-Gutiérrez JL, Gobartt AL, en representación del grupo de investigadores RIVASOL. Hábitos de prescripción de rivastigmina en solución en pacientes con demencia tipo Alzheimer en España (estudio RIVASOL). Rev Neurol 2007; 44: 705-10.
10. Franz CE, Barker JC, Kravitz RL, Flores Y, Krishnana S, Hinton L. Nonmedical influences on the use of cholinesterase inhibitors in dementia care. Alzheimer Dis Assoc Disord 2007; 21: 241-8.